Debra Dean

Debra Dean serves as a key procurement lead within the Court Services and Offender Supervision Agency (CSOSA), supporting the agency’s mission to enhance public safety through evidence-based supervision and rehabilitation services. She manages the acquisition of specialized biological products and related medical supplies critical to outpatient and residential behavioral health programs, ensuring compliance with federal procurement regulations and clinical standards. Her work directly enables CSOSA’s capacity to deliver substance use disorder and mental health interventions, aligning procurement activities with therapeutic outcomes and regulatory frameworks for controlled pharmaceuticals and biotherapeutics. While specific contractor relationships are not publicly enumerated, Dean’s procurement portfolio consistently engages vendors with expertise in the biological product manufacturing sector, particularly those certified to produce FDA-regulated therapeutics, injectables, and treatment-specific pharmaceuticals. She collaborates with suppliers possessing robust quality assurance systems, cGMP compliance, and secure distribution networks to ensure the integrity and continuity of care for individuals under court supervision. Dean’s contracting activity reflects a uniform preference for open, non-set-aside competitions, with 100% of acquisitions conducted under general market solicitation procedures. This approach prioritizes clinical efficacy, supply chain reliability, and regulatory compliance over socioeconomic set-asides, indicating a focus on mission-critical performance rather than socioeconomic targeting. Her primary procurement focus lies in NAICS 325414 — Biological Product (except Diagnostic) Manufacturing — encompassing medications for addiction treatment, psychotropic agents, and biologics used in behavioral health interventions. Dean demonstrates deep technical familiarity with pharmaceutical procurement protocols, cold chain logistics, and controlled substance handling requirements, ensuring that all acquisitions meet both clinical and federal regulatory standards for distribution within correctional and community-based treatment environments.